Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

acr

  • Home
  •  
  • acr



  • Most Read
  • Latest Comments
  • Quickfire FDA approval for Acrux’s testosterone sends share price soaring
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Quickfire FDA approval for Acrux’s testosterone sends share price soaring
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Quickfire FDA approval for Acrux’s testosterone sends share price soaring
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Quickfire FDA approval for Acrux’s testosterone sends share price soaring
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Quickfire FDA approval for Acrux’s testosterone sends share price soaring
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • BTC Health secures $5m ECMO contract with Royal Children’s Hospital for life-saving medtech
    BTC Health secures $5m ECMO contract with Royal Children’s Hospital for life-saving medtech
    • News

  • BTC Health drives earnings with product diversification to all major hospital operators
    BTC Health drives earnings with product diversification to all major hospital operators
    • News

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • SDI reports profit upgrade with cost cutting measure proving effective
    SDI reports profit upgrade with cost cutting measure proving effective
    • News

  • Mayne Pharma settles shareholder class action for $38M with no admission of guilt
    Mayne Pharma settles shareholder class action for $38M with no admission of guilt
    • News

  • Quickfire FDA approval for Acrux’s testosterone sends share price soaring
    • News

    Quickfire FDA approval for Acrux’s testosterone sends share price soaring

    Aussie pharmaceuticals company Acrux (ASX: ACR) is quickly making inroads through the lucrative American healthcare system with regulatory approval granted for their generic equivalent of a common testosterone topical solution which generates more than $25 million annually. Approval was granted from the Food and Drug administration for Acrux’s gel following their submission in August 2018

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.